KNSA NASDAQ
Credit Risk of going bust: lower than 91% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Total debt $8.9M against a stock market value of $5.69B.
Distance to default 14.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.4M (short-term plus half of long-term), stock volatility 47.9%; Altman Z'' 5.80. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
London, GL W1J 7NJ
GB
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Megna Michael R | S-Sale | 4,600 | $80.30 | 2026-09-03 |
| Ragosa Mark | M-Exempt | 2,694 | — | 2026-09-01 |
| Ragosa Mark | M-Exempt | 1,750 | — | 2026-09-01 |
| Ragosa Mark | M-Exempt | 1,591 | — | 2026-09-01 |
| Ragosa Mark | M-Exempt | 3,069 | — | 2026-09-01 |